The objectives of this presentation are to review:

1.  the basic pathophysiologic mechanisms that contibute to secondary damage after acute SCI

2.  clinical trials of acute neuroprotective or neuro-reparative agents that have either begun or will begin in the near future.

3.  the pitfalls in the interpretation of media reports of acute and chronic SCI therapies, and early non-randomized clinical trials.